Celebrates Major Milestone: Export Approval for Ponatinib Hydrochloride API (CAS 1114544-31-8)

Puri Pharmaceutical Co.,ltd today announced a significant achievement: the successful certification and approval for the global export of its Ponatinib Hydrochloride API (CAS 1114544-31-8).

This milestone marks a critical step in expanding access to this vital oncology ingredient worldwide. Ponatinib Hydrochloride is a potent, third-generation tyrosine kinase inhibitor (TKI) essential for the formulation of treatments for certain resistant forms of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

The approval, granted by the relevant national regulatory authorities, confirms that [Your Company Name]'s manufacturing facility and processes for Ponatinib Hydrochloride comply with international Good Manufacturing Practice (GMP) standards. This ensures that the API meets the stringent quality, safety, and efficacy requirements demanded by global pharmaceutical partners.

We are immensely proud to achieve this export license for Ponatinib Hydrochloride. This isn't just a business achievement; it's a commitment to the global health community. By enabling reliable access to this critical API, we are supporting pharmaceutical companies worldwide in their mission to bring life-saving treatments to patients who have developed resistance to prior therapies, particularly those with the T315I mutation. This accomplishment is a testament to our team's dedication to quality, innovation, and global health."

The ability to export Ponatinib Hydrochloride (CAS 1114544-31-8) is expected to:

• Strengthen      Global Supply Chains: Provide a reliable and high-quality source      for this essential oncology API, reducing dependencies on single      geographic regions.

• Support      Drug Development: Enable pharmaceutical companies globally to      develop and manufacture generic and branded formulations of Ponatinib,      potentially increasing competition and accessibility.

• Improve      Patient Access: Ultimately contribute to broader availability of      this crucial medication for patients in need across different markets.

Puri Pharmaceutical Co., Ltd has invested significantly in state-of-the-art technology and rigorous quality control systems to produce Ponatinib Hydrochloride to the highest pharmacopeial standards.

About Ponatinib Hydrochloride (CAS 1114544-31-8):
Ponatinib Hydrochloride is the active pharmaceutical ingredient in the branded drug Iclusig®. It is a multi-targeted kinase inhibitor renowned for its efficacy against the BCR-ABL1 tyrosine kinase, including the resistant T315I gatekeeper mutation. It is a critical therapeutic agent for patients with resistant or intolerant CML and Ph+ ALL.

Puri Pharmaceutical Co., Ltd is a specialized API manufacturer focused on the research, development, and production of high-potency, high-value generic and innovative APIs, particularly in the oncology segment. The company serves a global clientele with a robust portfolio of products manufactured in cGMP-compliant facilities.